Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

2020596 citationsJournal Articlehybrid Open Access

Authors

N+C significantly improved PFS and time to intervention for CNS disease versus L+C. No new N+C safety signals were observed.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 38, Issue 27, pp. 3138-3149

Field-Weighted Citation Impact: 32.76